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Abstract
Background
We aimed to describe the most frequently prescribed initial antiretroviral therapy (ART) regi-
mens in recent years in HIV-positive persons in the Cohort of the Spanish HIV/AIDS
Research Network (CoRIS) and to investigate factors associated with the choice of each
regimen.
Methods
We analyzed initial ART regimens prescribed in adults participating in CoRIS from 2014 to
2017. Only regimens prescribed in >5% of patients were considered. We used multivariable
multinomial regression to estimate Relative Risk Ratios (RRRs) for the association between
sociodemographic and clinical characteristics and the choice of the initial regimen.
Results
Among 2874 participants, abacavir(ABC)/lamivudine(3TC)/dolutegavir(DTG) was the most
frequently prescribed regimen (32.1%), followed by tenofovir disoproxil fumarate (TDF)/
emtricitabine (FTC)/elvitegravir(EVG)/cobicistat(COBI) (14.9%), TDF/FTC/rilpivirine (RPV)
(14.0%), tenofovir alafenamide (TAF)/FTC/EVG/COBI (13.7%), TDF/FTC+DTG (10.0%),
TDF/FTC+darunavir/ritonavir or darunavir/cobicistat (bDRV) (9.8%) and TDF/FTC+raltegra-
vir (RAL) (5.6%).
Compared with ABC/3TC/DTG, starting TDF/FTC/RPV was less likely in patients with
CD4<200 cells/μL and HIV-RNA>100.000 copies/mL. TDF/FTC+DTG was more frequent in
those with CD4<200 cells/μL and HIV-RNA>100.000 copies/mL. TDF/FTC+RAL and TDF/
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FTC+bDRV were also more frequent among patients with CD4<200 cells//μL and with trans-
mission categories other than men who have sex with men. Compared with ABC/3TC/DTG,
the prescription of other initial ART regimens decreased from 2014–2015 to 2016–2017 with
the exception of TDF/FTC+DTG. Differences in the choice of the initial ART regimen were
observed by hospitals’ location.
Conclusions
The choice of initial ART regimens is consistent with Spanish guidelines’ recommendations,
but is also clearly influenced by physician’s perception based on patient’s clinical and socio-
demographic variables and by the prescribing hospital location.
Introduction
International and local guidelines for the treatment of HIV-infection provide recommenda-
tions on the preferred drug combinations for initial antiretroviral therapy (ART) of treatment-
naïve patients [1,2]. Although there is a wide range of highly effective and well tolerated thera-
pies, most recent guidelines in Spain and the United States have limited preferred options to
integrase inhibitor-based regimens based on the results of clinical trials as well as on the
advantages of individual drugs [3,4]. Other guidelines such as the ones from the European
AIDS Clinical Society also include regimens based on rilpivirine and boosted darunavir as pre-
ferred [2]. Some experts and clinicians feel that current recommendations might be too restric-
tive and regimens other than those based on integrase inhibitors would be at least as good
choices to initiate therapy in most patients.
Previous studies have shown that the decision on what specific ART regimen is prescribed
to each patient can be influenced by a variety of factors, not only dependent on the patient
(such as comorbidities, HIV stage, concerns about toxicity or drug interactions, risk of nonad-
herence, patient’s preference) but also on the prescribing physician (such as HIV treatment
experience, budget limitations, hospital’s characteristics, physician’s preference) [5,6]. The few
studies that have investigated the factors influencing the choice of initial ART were published
before newer drugs such as rilpivirine and integrase inhibitors were widely used [5,7–9], and
there is no evidence on the factors that could influence the choice of ART with the more recent
treatment regimens, and specifically with those including an integrase inhibitor.
In this study, we aimed to describe the most frequently prescribed initial ART regimens in
recent years in HIV-positive patients in the Cohort of the Spanish HIV/AIDS Research Net-
work (CoRIS) and to investigate factors associated with the choice of initial ART.
Methods
Study design
CoRIS is an open, multicentre, prospective cohort of ART-naïve HIV-positive adults recruited
in 45 centres from 13 of the 17 Autonomous Regions of Spain. Patients are followed periodi-
cally in accordance with routine clinical practice. Data are subject to internal quality control.
A complete description of the cohort has been published elsewhere [10,11].
Initial antiretroviral treatment choice
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Study population
Patients included were antiretroviral-naïve, aged� 18 years, and had started ART between 1st
September 2014 (when DTG became available in Spain) and 30th November 2017 with the
most commonly used first-line antiretroviral regimens. In order to facilitate the analyses, only
regimens prescribed in >5% of individuals were considered. Patients with no follow-up after
initiation of ART were excluded.
Definition of variables
The primary endpoint was the choice of the initial ART according to the most frequently pre-
scribed regimens: abacavir (ABC) /lamivudine (3TC) /dolutegavir (DTG) was the most fre-
quently prescribed ART, followed by tenofovir disoproxil fumarate (TDF) /emtricitabine
(FTC)/ elvitegravir (EVG)/ cobicistat (COBI), TDF/FTC/rilpivirine (RPV), tenofovir alafena-
mide(TAF)/FTC/EVG/COBI, TDF/FTC+DTG, TDF/FTC+darunavir/ritonavir or darunavir/
cobicistat (bDRV) and TDF/FTC+raltegravir (RAL).
Possible explanatory variables included sex (male, female), age at ART initiation (<30, 30–
49,�50 years), transmission category (men who have sex with men [MSM], heterosexual,
injecting drug use, other, unknown), educational level (no education or compulsory education,
upper secondary or university education, unknown), origin (Spain, immigrants, unknown),
CD4 T-cell count (<200,�200 cells/μL, unknown) and viral load (�100,000, >100,000 cop-
ies/mL, unknown), presence of hepatitis C virus antibodies (no, yes, unknown), presence of
hepatitis B virus surface antigen (HBVSA) (no, yes, unknown), triglycerides (�150, >150 mg/
dL, unknown), HDL (�40,>40 mg/dL, unknown) and total cholesterol (�200, >200 mg/dL,
unknown) within 6 months previous to ART initiation, AIDS diagnosis at ART initiation (no,
yes), presence of comorbidities (cardiovascular, nephrology, neurologic [no, yes]), period of
ART initiation (2014–2015,2016–2017) and hospital characteristics (number of beds [<500,
�500] and hospital’s location [Autonomous region]).
Statistical analysis
Descriptive analysis of patients’ characteristics was carried out using frequency tables for cate-
gorical variables and median and interquartile range for continuous variables. Differences in
socio-demographic and clinical characteristics according to initial regimen were assessed with
the non-parametric Kruskal-Wallis test for continuous variables and the chi-squared test for
independence for categorical variables. We used multivariable multinomial regression to esti-
mate Relative Risk Ratios (RRRs) for the association between explanatory variables and the
choice of the initial regimen. All variables that retained a significant independent association
(p<0.05) were included in the final model.
Heterogeneity introduced by different hospitals was accounted for by including the study
hospital as a fixed effect in the model and by using robust methods to estimate standard errors
and, thus, to calculate 95% confidence intervals and p-values.
All statistical analyses were performed using Stata software (version 15.0; Stata Corporation,
College Station, Texas, USA).
Ethics
Ethics approval was obtained from all hospitals’ Ethics’ Committees and every patient pro-
vided written informed consent to participate in the cohort. This study was approved by the
Ethics Committee of Instituto de Salud Carlos III (CEI PI 63_2017-v2).
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Results
Between September 1, 2014 and November 30, 2017, 3,575 patients aged�18 years initiated
treatment; among these, 147 (4.1%) with no follow-up after ART initiation and 554 (15.5%)
who initiated a treatment prescribed in<5% of patients were excluded. The final analysis
included 2,874 (80.4%) subjects who initiated ART during the period of study. They were pre-
dominantly male (88.5%) and 59.7% were from Spain. Transmission route was heterosexual
contact in 23.5% and MSM in 68.9%. At treatment initiation, median age was 36 years (inter-
quartile range [IQR]: 30–44), median CD4+ T-cell count was 416 cells/μL (IQR: 243–591),
8.5% of patients had a history of AIDS diagnosis, 34.5% had a viral load>100,000 copies/mL
and 89.2% were attending hospitals with more than 500 beds.
The most frequently prescribed initial regimens in the study period and the differences in
sociodemographic and clinical characteristics of patients according to their initial ART regi-
men are shown in Table 1. TDF/FTC+bDRV and TDF/FTC+RAL were significantly less often
used in participants with upper education and among MSM. TAF/FTC/EVG/COBI was more
likely prescribed among immigrants and TDF/FTC+RAL among those aged 50 years or older.
As expected, rilpivirine was rarely used in patients with high baseline viral load >100,000
copies/mL (2.5%) or CD4 counts <200 cells/μL (4.0%). A higher proportion of the patients
starting TDF/FTC+DTG, TDF/FTC+bDRV and TDF/FTC+RAL had a CD4 cell count below
200 cells/μL and an AIDS diagnosis at start of treatment. TDF/FTC+DTG and TDF/FTC
+RAL were more frequent in participants with triglycerides >150 mg/dL and cholesterol-
HDL�40 mg/dL. Large differences in the prescription of initial regimen were noted by hospi-
tal location but not by hospital size. There were also differences in the use of initial regimen in
relation to HBVSA and previous cardiovascular event; nevertheless they must be interpreted
with caution as the number of events was small.
We also observed changes over time in the distribution of the most frequent initial ART
regimens (Fig 1). In the period 2014–2015, TDF/FTC/RPV (25.3%) and TDF/FTC/EVG/
COBI (25.2%) were the most frequently prescribed initial ART, followed by ABC/3TC/DTG
(21.6%). However, in the period 2016–2017, the most frequent regimen was ABC/3TC/DTG
(40.0%), followed by TAF/FTC/EVG/COBI (23.8%). When grouping the regimens by their
third agent, the only regimens whose prescription increased over time were the ones based in
DTG (including ABC/3TC/DTG and TDF/FTC+DTG) and EVG (including TDF/FTC/EVG/
COBI and TAF/FTC/EVG/COBI), while the prescription of all other regimens decreased. Reg-
imens based in DTG increased from being prescribed in 29.1% of the patients in 2014–2015 to
51.8% in 2016–2017, and those based in EVG increased from 25.2% to 30.9%, respectively
(Fig 1).
Results from multivariable analysis are shown in Table 2. Compared with ABC/3TC/DTG,
starting TDF/FTC/RPV was less likely in patients with CD4 counts <200 cells/μL (RRR, 95%
CI: 0.41, 0.25–0.67) and with HIV-RNA >100.000 copies/mL (RRR, 95% CI: 0.05, 0.03–0.10);
inversely TDF/FTC+DTG was more frequent in those with CD4 counts <200 cells/μL (RRR,
95% CI: 3.35, 2.34–4.80) and with HIV-RNA >100.000 copies/mL (RRR, 95% CI: 1.74, 1.21–
2.52). TDF/FTC+RAL and TDF/FTC+bDRV were also more likely to be prescribed among
patients with CD4 counts <200 cells/μL (RRR, 95% CI: 3.76, 2.39–5.92 and RRR, 95% CI: 2.61,
1.51–4.49, respectively) and those with transmission categories other than MSM (RRR, 95%
CI: 2.00, 1.29–3.10 and RRR, 95% CI: 1.73, 1.14–2.61, respectively). Compared with ABC/
3TC/DTG, the prescription of other initial ART regimens decreased over time (p<0.001), with
the exception of TDF/FTC+DTG (p = 0.173). Valid conclusions regarding changes over time
in the prescription of TAF/FTC/EVG/COBI could not be drawn because it was widely avail-
able only after 2016. Overall differences in the choice of the initial ART regimen were observed
Initial antiretroviral treatment choice
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by hospital’s location. No other significant factors were found for the choice of TDF/FTC/
EVG/COBI and TAF/FTC/EVG/COBI, compared to ABC/3TC/DTG.
Discussion
This is, to our knowledge, the first study assessing the factors influencing the choice of initial
ART in a reasonable large cohort in recent years, when newer treatment regimens have
Table 1. Baseline characteristics of 2,874 study participants according to the initial antiretroviral regimen.
ABC/3TC/
DTG
TDF/FTC/EVG/
COBI
TDF/FTC/
RPV
TAF/FTC/EVG/
COBI
TDF/FTC
+DTG
TDF/FTC
+bDRV
TDF/FTC
+RAL
P
923 (32.1%) 427 (14.9%) 401 (14.0%) 394 (13.7%) 287 (10.0%) 282 (9.8%) 160 (5.6%)
Male sex 815 (88.3%) 393 (92.0%) 365 (91.0%) 345 (87.6%) 253 (88.2%) 248 (87.9%) 125 (78.1%) <0.001
Upper education 518 (56.1%) 242 (56.7%) 215 (53.6%) 232 (58.9%) 155 (54.0%) 125 (44.3%) 70 (43.8%) 0.033
Immigrants 339 (36.7%) 172 (40.3%) 151 (37.7%) 191 (48.5%) 109 (38.0%) 101 (35.8%) 61 (38.1%) 0.003
Men who have sex with men 659 (71.4%) 324 (75.9%) 289 (72.1%) 278 (70.6%) 191 (66.6%) 154 (54.6%) 84 (52.5%) <0.001
Age�50 years-old 117 (12.7%) 33 (7.7%) 40 (10.0%) 41 (10.4%) 45 (15.7%) 45 (16.0%) 31 (19.4%) <0.001
AIDS 53 (5.7%) 28 (6.6%) 3 (0.7%) 19 (4.8%) 54 (18.8%) 41 (14.5%) 47 (29.4%) <0.001
Median CD4 (IQR) 443 (283–609) 445 (274–590) 506 (378–719) 430 (265–591) 286 (94–473) 296 (111–492) 230 (72–449) <0.001
CD4 count <200 cells/μL 120 (13.0%) 71 (16.6%) 16 (4.0%) 65 (16.5%) 107 (37.3%) 94 (33.3%) 68 (42.5%) <0.001
Viral load >100,000 copies/
mL
317 (34.3%) 147 (34.4%) 10 (2.5%) 154 (39.1%) 155 (54.0%) 131 (46.5%) 77 (48.1%) <0.001
Triglycerides >150 mg/dL 154 (16.7%) 65 (15.2%) 54 (13.5%) 62 (15.7%) 69 (24.0%) 48 (17.0%) 39 (24.4%) <0.001
HDL cholesterol �40 mg/dL 419 (45.4%) 147 (34.4%) 128 (31.9%) 168 (42.6%) 139 (48.4%) 129 (45.7%) 74 (46.3%) <0.001
Total cholesterol >200 mg/
dL
113 (12.2%) 49 (11.5%) 47 (11.7%) 49 (12.4%) 27 (9.4%) 32 (11.3%) 21 (13.1%) 0.941
HCV + antibody 46 (5.0%) 21 (4.9%) 23 (5.7%) 19 (4.8%) 16 (5.6%) 19 (6.7%) 14 (8.8%) 0.073
HBV S + antigen 3 (0.3%) 11 (2.6%) 13 (3.2%) 6 (1.5%) 12 (4.2%) 5 (1.8%) 5 (3.1%) 0.551
Cardiovascular event 14 (1.5%) 9 (2.1%) 5 (1.2%) 6 (1.5%) 9 (3.1%) 5 (1.8%) 11 (6.9%) <0.001
Renal event 17 (1.8%) 10 (2.3%) 5 (1.2%) 8 (2.0%) 7 (2.4%) 3 (1.1%) 7 (4.4%) 0.258
Neurologic event 33 (3.6%) 14 (3.3%) 12 (3.0%) 8 (2.0%) 15 (5.2%) 8 (2.8%) 10 (6.3%) 0.151
Hospital size < = 500 beds 834 (90.4%) 377 (88.3%) 352 (87.8%) 340 (86.3%) 268 (93.4%) 250 (88.7%) 143 (89.4%) 0.081
Hospitals’ location� <0.001
A 123 (13.3%) 118 (27.6%) 67 (16.7%) 124 (31.5%) 22 (7.7%) 26 (9.2%) 17 (10.6%)
B 2 (0.2%) 1 (0.2%) 3 (0.7%) 2 (0.5%) 0 (0.0%) 2 (0.7%) 0 (0.0%)
C 11 (1.2%) 0 (0.0%) 5 (1.2%) 1 (0.3%) 6 (2.1%) 17 (6.0%) 0 (0.0%)
D 9 (1.0%) 1 (0.2%) 2 (0.5%) 0 (0.0%) 4 (1.4%) 4 (1.4%) 0 (0.0%)
E 87 (9.4%) 62 (14.5%) 36 (9.0%) 36 (9.1%) 16 (5.6%) 27 (9.6%) 18 (11.3%)
F 22 (2.4%) 12 (2.8%) 19 (4.7%) 5 (1.3%) 5 (1.7%) 2 (0.7%) 6 (3.8%)
G 104 (11.3%) 19 (4.4%) 21 (5.2%) 26 (6.6%) 9 (3.1%) 9 (3.2%) 0 (0.0%)
H 22 (2.4%) 0 (0.0%) 7 (1.7%) 0 (0.0%) 20 (7.0%) 3 (1.1%) 1 (0.6%)
I 407 (44.1%) 159 (37.2%) 131 (32.7%) 146 (37.1%) 138 (48.1%) 56 (19.9%) 49 (30.6%)
J 40 (4.3%) 19 (4.4%) 6 (1.5%) 17 (4.3%) 26 (9.1%) 15 (5.3%) 6 (3.8%)
K 25 (2.7%) 0 (0.0%) 12 (3.0%) 3 (0.8%) 0 (0.0%) 23 (8.2%) 21 (13.1%)
L 5 (0.5%) 0 (0.0%) 56 (14.0%) 0 (0.0%) 0 (0.0%) 67 (23.8%) 32 (20.0%)
M 66 (7.2%) 36 (8.4%) 36 (9.0%) 34 (8.6%) 41 (14.3%) 31 (11.0%) 10 (6.3%)
Period of ART initiation-
2016–17
657 (71.2%) 116 (27.2%) 89 (22.2%) 391 (99.2%) 194 (67.6%) 128 (45.4%) 67 (41.9%) <0.001
�Each capital letter identifies one of the Autonomous Regions. The names of the Autonomous Regions cannot be disclosed due to confidentiality reasons
https://doi.org/10.1371/journal.pone.0221598.t001
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become widely available. All the regimens analyzed were considered preferred or alternative
by the Spanish treatment guidelines during the study period [1,12–14], but our results suggest
that the choice between different regimens could be influenced by certain characteristics of the
patient or the hospitals where the treatment is initiated, in addition to the efficacy and toxicity
results shown in clinical trials.
Overall, ABC/3TC/DTG was the most frequently prescribed regimen. Interestingly, the pre-
scription of initial regimens changed over the calendar period. Over time, the prescription of
regimens based in DTG and EVG increased. TDF/FTC/EVG/COBI prescription decreased
but this was probably partly due to the introduction of TAF/FTC/EVG/COBI, which became
available in Spain in 2016. The prescription of the other regimens (TDF/FTC/RPV, TDF/FTC
+bDRV and TDF/FTC+RAL) decreased over time. These changes reflect those introduced in
the Spanish HIV treatment guidelines. In 2014, all the regimens included in this study were
considered preferred treatments [12]. However, since 2015 the guidelines became much more
restrictive and have only recommended regimens based on integrase inhibitors as preferred,
and have classified all the other regimens analyzed as alternative [1,13,14]. Despite being a pre-
ferred regimen, TDF/FTC+RAL was prescribed much less than the regimens based in DTG or
EVG. This is probably due to the availability of these latter drugs as part of single tablet
regimens.
Different regimens were preferentially prescribed to certain groups. The use of integrase
inhibitors was more frequent among MSM. This could be in part due to patients’ preference,
as MSM frequently have more access to information about HIV [8] and could be more
informed about new treatments (and request them to their physicians) than other risk groups.
TDF/FTC+RAL, TDF/FTC+bDRV and TDF/FTC+DTG were more likely to be prescribed
to patients with low CD4 counts. The use of TDF/FTC is probably due to the need to initiate
Fig 1. Distribution of the initial antiretroviral treatment by period of ART initiation.
https://doi.org/10.1371/journal.pone.0221598.g001
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Table 2. Multivariable relative risk ratios for predictors of the choice of the initial ART regimen relative to ABC/3TC/DTG.
TDF/FTC/EVG/
COBI
TDF/FTC/RPV TAF/FTC/EVG/
COBI
TDF/FTC+DTG TDF/FTC+bDRV TDF/FTC+RAL
RRR (IC
95%)
P RRR (IC 95%) P RRR (IC
95%)
P RRR (IC
95%)
P RRR (IC 95%) P RRR (IC 95%) P
HIV transmission
category
MSM 1 1 1 1 1 1
Non-MSM 0.96 (0.67–
1.39)
0.833 1.10 (0.79–
1.54)
0.575 1.10 (0.78–
1.54)
0.598 0.98 (0.69–
1.38)
0.892 1.73 (1.14–
2.61)
0.009 2.00 (1.29–
3.10)
0.002
CD4 T-cell count
> = 200 cells/μL 1 1 1 1 1 1
<200 cells/μL 1.28 (0.97–
1.70)
0.085 0.41 (0.25–
0.67)
<0.001 1.18 (0.84–
1.66)
0.331 3.35 (2.34–
4.80)
<0.001 2.61 (1.51–
4.49)
0.001 3.76 (2.39–
5.92)
<0.001
Viral Load
< = 100,000 cop/
mL
1 1 1 1 1 1
>100,000 cop/mL 1.03 (0.72–
1.48)
0.869 0.05 (0.03–
0.10)
<0.001 1.15 (0.87–
1.52)
0.330 1.74 (1.21–
2.52)
0.003 1.21 (0.84–
1.75)
0.300 1.16 (0.70–
1.91)
0.566
Period of ART
initiation
2014–2015 1 1 1 1 1 1
2016–2017 0.17 (0.12–
0.22)
<0.001 0.09 (0.05–
0.15)
<0.001 NA 0.79 (0.57–
1.11)
0.173 0.22 (0.12–
0.42)
<0.001 0.23 (0.12–
0.42)
<0.001
Hospitals’ location� <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
A 1 1 1 1 1 1
B 1.17 (0.84–
1.63)
7.02 (4.87–
10.12)
0.57 (0.39–
0.85)
NA 9.25 (4.43–
19.32)
NA
C NA 2.06 (0.71–
5.95)
0.05 (0.02–
0.12)
3.96 (1.30–
12.03)
10.54 (3.34–
33.30)
NA
D 0.22 (0.15–
0.31)
0.98 (0.73–
1.31)
NA 3.38 (1.85–
6.18)
4.34 (2.14–
8.79)
NA
E 1.08 (0.57–
2.04)
1.37 (0.35–
5.42)
0.28 (0.16–
0.51)
1.00 (0.39–
2.55)
1.60 (0.45–
5.64)
1.53 (0.69–
3.40)
F 0.70 (0.21–
2.34)
2.12 (1.31–
3.43)
0.18 (0.07–
0.44)
1.28 (0.66–
2.51)
0.43 (0.03–
6.69)
1.78 (0.89–
3.56)
G 0.28 (0.21–
0.39)
0.71 (0.55–
0.93)
0.18 (0.12–
0.27)
0.54 (0.31–
0.93)
0.50 (0.27–
0.92)
NA
H NA 1.10 (0.83–
1.46)
NA 5.87 (3.38–
10.17)
0.75 (0.39–
1.42)
0.38 (0.18–
0.78)
I 0.60 (0.30–
1.20)
1.08 (0.73–
1.61)
0.26 (0.13–
0.51)
2.01 (0.93–
4.36)
0.85 (0.39–
1.87)
1.15 (0.47–
2.84)
J 0.80 (0.39–
1.66)
0.63 (0.32–
1.21)
0.30 (0.12–
0.74)
3.59 (1.45–
8.86)
2.15 (1.06–
4.35)
1.38 (0.42–
4.53)
K NA 2.23 (1.61–
3.08)
0.08 (0.05–
0.12)
NA 5.12 (2.67–
9.82)
6.97 (3.32–
14.65)
L NA 78.87 (28.19–
220.65)
NA NA 101.92 (17.62–
589.58)
71.74 (26.53–
194.01)
M 0.77 (0.25–
2.43)
1.60 (0.60–
4.27)
0.39 (0.15–
1.01)
3.73 (1.49–
9.33)
2.66 (0.73–
9.74)
1.25 (0.32–
4.88)
�Each capital letter identifies one of the Autonomous Regions. The names of the Autonomous Regions cannot be disclosed due to confidentiality reasons
https://doi.org/10.1371/journal.pone.0221598.t002
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treatment promptly when results from HLA B5701 are not yet available, and RAL and DTG
could probably be used to minimize interactions in patients that might be being treated for
other opportunistic diseases. Also, prevalence of resistance to integrase inhibitors is low in
Spain [15,16] and these agents are frequently prescribed when resistance tests are still pending.
The prescription of TDF/FTC+bDRV for patients with low CD4 counts reached borderline
statistical significance, probably due to the high genetic barrier of protease inhibitors that
allows their use in severely immunosuppressed patients while waiting for resistance test results,
as described in earlier studies[5].
The choice of regimens varied significantly by hospital location. This is not explained by
local variations in clinical characteristics of the patients, as these differences were still large
after adjusting for all other factors. Possible explanations include regional variations on the
physicians’ perceptions of efficacy and safety of different regimens[17], different experience on
HIV treatment among the treating physicians, and institutional constraints. Although we
could not assess limitations to ART prescription in all the participating hospitals for the study
period, we have recently described the limitations for the prescription of antiretrovirals in the
CoRIS cohort for the period 2010–2015: 54.1% of the centres had a cost limitation for the pre-
scription of ART and 29.7% had restricted access to at least one antiretroviral or single-tablet
regimen (mainly some of the newest integrase inhibitors)[18,19]. Although we could not ana-
lyze the influence of institutional constraints in the results of this study, it is possible that they
could have an influence in the choice of the initial ART: our previous study demonstrated that
hospitals with restricted access to at least one antiretroviral were more likely to prescribe ART
regimens that were not recommended by the Spanish clinical guidelines[19].
Our study is limited by the lack of information on individual physician’s characteristics,
and some clinical variables that could influence the choice of ART such as pregnancy, resis-
tance testing or other drugs that could interact with ART. However, our strengths include the
analysis of a reasonably large number of patients from a multicenter well established cohort,
and the recent time period which allow us to analyze the newer treatment regimens. Our
results suggest that initial ART prescriptions are influenced by clinical and demographic
patient variables, and also by the prescribing hospital location.
In conclusion, in this multicenter Spanish cohort the prescription of initial ART regimens
varied not only with patients’ clinical and demographic characteristics, but also with other var-
iables such as the period of ART initiation and hospital location. Over time, regimens based
on integrase inhibitors have become the most frequent choice as initial ART.
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